Weight Loss With Risedronate for Bone Health

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

July 22, 2020

Study Completion Date

July 22, 2020

Conditions
Bariatric Surgery CandidateBone LossWeight Loss
Interventions
DRUG

Risedronate Sodium 150 MG

Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.

OTHER

Placebo

Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.

Trial Locations (1)

27106

Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

Wake Forest University

OTHER

lead

Wake Forest University Health Sciences

OTHER

NCT03411902 - Weight Loss With Risedronate for Bone Health | Biotech Hunter | Biotech Hunter